Foley hosted the final session in the M&A Fusion Web Conference Series titled, “Intellectual Property Strategies to Maximize M&A Value” on December 13, 2007.
Foley attorneys Stephen B. Maebius, an Intellectual Property (IP) partner and co-chair of the Life Sciences Industry Team, and Christopher C. Cain, a partner and member of the Transactional & Securities, Commercial Transactions & Business Counseling, and Information Technology & Outsourcing Practices, offered innovative ideas and strategies for the most challenging IP and M&A questions. Each attorney comes to the table with extensive experience in complex patent prosecution matters and multifaceted M&A transactions.
Topics included:
- Pre-sale suggestions for sellers to enhance value and avoid deal-breaker issues in due diligence
- Buyer and seller perspectives on driving desired valuation through the due diligence process
- Mapping patents against products to ascertain value
- Updating IP to fully cover products, including patents, copyrights, and trademarks
- Patent infringement and ways to work around patents
- Uncovering hidden defects and risks in patents
- Inventorship and ownership of IP
- Going beyond the formalities to fully cover and safeguard your IP
People
Related Insights
June 6, 2025
Energy Current
House Bill 3809 Adds Obligations to Battery Energy Storage Lessees in Texas
On May 29, 2025, House Bill No. 3809 was signed into law by Texas Governor Greg Abbott. Born out of a crop of bills regulating renewable…
June 23, 2025
Events
Third Annual Transaction Solutions Symposium
Foley & Lardner is sponsoring the Third Annual Transaction Solutions Symposium — a premier conference focused on de-risking strategies that enhance deal execution and business outcomes. Rishi Sodhi will be speaking as part of the Tax Liability Insurance: Current Trends, Controversies and Claims panel.
June 5, 2025
Health Care Law Today
GLP-1 Compounded Medications Targeted by Connecticut Attorney General
On May 21, 2025, the Connecticut Office of the Attorney General released a statement and sent letters to Connecticut weight loss clinics, med spas, medical practices and other businesses regarding allegedly or potentially unfair and deceptive conduct relating to compounded GLP-1 medications.